Mechanisms of myeloid leukemogenesis: Current perspectives and therapeutic objectives.

Blood Rev · 2023 · PMC10693933 · PMID 35989139

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Smaller studies have suggested that hypomethylating agents may have utility in treating patients with AML and DNMT3A mutations, given their superior overall response rate and median overall survival compared to DNMT3A -wild type patients, although these results did not reach statistical significance [ 27 ]. 2.3.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.